Spyre Therapeutics, Inc.
SYRE
Price:
$15.18
Market Cap:
$916.17M
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; S...[Read more]
Industry
Biotechnology
IPO Date
2016-04-07
Stock Exchange
NASDAQ
Ticker
SYRE
PE Ratio
[-4.96]
ROE
[-49.10%]
Current Ratio
[8.06]
Dividend Yield
[0%]
Enterprise Value
[867.67M]
Dividend History
The PE Ratio as of May 2025 (TTM) for Spyre Therapeutics, Inc. (SYRE) is -4.96
According to Spyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.96. This represents a change of -75.94% compared to the average of -20.62 of the last 4 quarters.
Spyre Therapeutics, Inc. (SYRE) Historical PE Ratio (quarterly & annually)
How has SYRE PE Ratio performed in the past?
The mean historical PE Ratio of Spyre Therapeutics, Inc. over the last ten years is -7.42. The current -4.96 PE Ratio has changed 6.58% with respect to the historical average. Over the past ten years (40 quarters), SYRE's PE Ratio was at its highest in in the December 2015 quarter at 0. The PE Ratio was at its lowest in in the December 2024 quarter at -38.70.
Average
-7.42
Median
-3.32
Minimum
-41.90
Maximum
-0.45
Spyre Therapeutics, Inc. (SYRE) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Spyre Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 8.89%
Maximum Annual PE Ratio = -0.45
Minimum Annual Increase = -90.47%
Minimum Annual PE Ratio = -41.90
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -41.90 | 8.89% |
| 2023 | -0.47 | 3.04% |
| 2022 | -0.45 | -90.47% |
| 2021 | -4.75 | -8.60% |
| 2020 | -5.19 | 66.46% |
| 2019 | -3.12 | -11.30% |
| 2018 | -3.52 | 17.03% |
| 2017 | -3.00 | 53.08% |
| 2016 | -1.96 | -80.14% |
| 2015 | -9.89 | -23.46% |
Spyre Therapeutics, Inc. (SYRE) Average PE Ratio
How has SYRE PE Ratio performed in the past?
The current PE Ratio of Spyre Therapeutics, Inc. (SYRE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.27
5-year avg
-10.55
10-year avg
-7.42
Spyre Therapeutics, Inc. (SYRE) PE Ratio vs. Peers
How is SYRE’s PE Ratio compared to its peers?
Spyre Therapeutics, Inc.’s PE Ratio is
| Company | PE Ratio | Market cap |
|---|
Build a custom stock screener for Spyre Therapeutics, Inc. (SYRE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Spyre Therapeutics, Inc. (SYRE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Spyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Spyre Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Spyre Therapeutics, Inc. (SYRE)?
What is the highest PE Ratio for Spyre Therapeutics, Inc. (SYRE)?
What is the 3-year average PE Ratio for Spyre Therapeutics, Inc. (SYRE)?
What is the 5-year average PE Ratio for Spyre Therapeutics, Inc. (SYRE)?
How does the current PE Ratio for Spyre Therapeutics, Inc. (SYRE) compare to its historical average?